Login to Your Account

Accera's NOURISH trial meets a bitter end

By Michael Fitzhugh
Staff Writer

Tuesday, February 28, 2017

Accera Inc.'s metabolic-focused Alzheimer's candidate, AC-1204, has foundered in the company's phase III NOURISH AD trial, failing to deliver statistically significant improvements in memory and cognition vs. placebo for people with mild to moderate Alzheimer's disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription